Age and Response to Flu Vaccines

• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT03328325
• Collaborator: (none)
• Enrollment: 152
• Locations: 2
• Arm: 1
• Actual Duration (Months): 28.2
• Patients Per Site: 76
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary objective of this study is to evaluate the relationship between first influenza A virus exposure (inferred by age), vaccine history, and baseline serum antibody response to seasonal influenza vaccine in healthy adults and children.

Condition or Disease	Intervention/Treatment	Phase
Influenza; Influenza Immunisation	Biological: Influenza Virus Quadrivalent Inactivated Vaccine; Biological: Influenza Virus Quadrivalent Inactivated Vaccine	Phase 4

Detailed Description

The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary hypothesis being tested in this study is that there will be differences in the specificity and magnitude of the HA-specific B cell response depending on the age, previous vaccine history and baseline B cell reactivity. The primary objective of this study is to evaluate the relationship between first influenza A virus exposure (inferred by age), vaccine history, and baseline serum antibody response to seasonal influenza vaccine in healthy adults and children. The secondary objective is to evaluate factors related to failure of vaccine to provide protection against symptomatic influenza and the immune response to infection in vaccinated individuals by prospective surveillance of the vaccine cohort.

Study Design

• Study Type: Interventional
• Actual Enrollment: 152 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on the B Cell Response to Inactivated Influenza Vaccine in Healthy Adults and Children
• Actual Study Start Date: Dec 14, 2017
• Actual Primary Completion Date: Feb 9, 2020
• Actual Study Completion Date: Apr 20, 2020

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Arm 1 0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240

Biological: Influenza Virus Quadrivalent Inactivated Vaccine; A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.; Biological: Influenza Virus Quadrivalent Inactivated Vaccine; A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.

Outcome Measures

Primary Outcome Measures

1. Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) [Through Day 28]

   A/Hong Kong/4801/2014 (H3N2) day 28 Season 2017-2018

2. Magnitude of the Serum Antibody Response by Microneutralization (MN) [Day 28]

   A/Hong Kong/4801/2014 (H3N2) Day 28 MN Season 2017-2018

3. Serum Antibody Response by Hemagglutination-inhibition (HAI) [Day 90]

   A/Hong Kong/4801/2014 (H3N2) Day 90 Season 2017-2018

4. Serum Antibody Response by Microneutralization (MN) [Day 90]

   A/Hong Kong/4801/2014 (H3N2) Day 90 MN Season 2017-2018

5. Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI) [Day 28]

   A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-2018

6. Specificity of the Serum Antibody Response by Microneutralization (MN) [Day 28]

   A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-18

Secondary Outcome Measures

1. Age at Time of First Influenza A Exposure [Baseline]

   Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not

2. Baseline B Cell Reactivity [Baseline]

   Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not

3. Vaccine History (Number and Percentage of Participants to Receive Vaccine) [Baseline]

   Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not

Eligibility Criteria

Criteria

• Ages Eligible for Study: 9 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Aged equal to or greater than 9 years of age and weigh at least 50 pounds

2. The subject must be in good health, as determined by: medical history; and targeted physical examination, when necessary, based on medical history. Stable medical or psychiatric condition is defined as: no recent increase in prescription medication, dose, or frequency of medication in the last 3 months and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months

3. The subject is able to understand and comply with the planned study procedures, including being available for all study visits

4. The subject/parent has provided informed consent/assent prior to any study procedures

5. Subjects who have not received seasonal flu vaccine for the current year

Exclusion Criteria:

1. Subject report of known hypersensitivity to allergy to components of the study vaccine or other components of the study vaccine

2. Subject report of known latex allergy

3. Subject report of a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines

4. Subject report of a history of Guillain-Barre syndrome within 6 weeks of receipt of a previous influenza vaccine

5. The subject is a female of childbearing potential who is currently pregnant or breastfeeding or intends to become pregnant during the study period between enrollment and 90 days following receipt of vaccine. Pregnancy will be determined by subject interview. Pregnancy testing is not done in this study since there is no increased risk in pregnancy

6. The subject is immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months

7. The subject has an active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. For this criterion, "active" is defined as having received treatment within the past 5 years

8. Have taken high-dose inhaled corticosteroids within 30 days prior to study vaccination. High-dose defined as per age as using inhaled high dose per reference chart https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/quick-refere nce-html#estimated-comparative-daily-doses

9. The subject received immunoglobulin or another blood product within the 3 months prior to enrollment in this study

10. The subject has received an inactivated vaccine within the 2 weeks or a live vaccine within the 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days after vaccination

11. The subject has an acute or chronic medical condition that, in the opinion of the investigator or appropriate sub-investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions include any acute or chronic medical disease or conditions defined as persisting for 3 months (defined as 90 days) or longer, that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses of the subject's successful completion of the study

12. Subjects with an active infection or that has an acute illness or an oral temperature greater than 99.9 degrees Fahrenheit (37.7 degrees Celsius) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated symptoms resolved are eligible to enroll as long as treatment is completed and symptoms resolved > 3 days prior to enrollment

13. The subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period

14. The subject has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol

15. The subject has a history of alcohol or drug abuse in the 5 years prior to enrollment

16. The subject has a known human immunodeficiency virus, hepatitis B, or hepatitis C infection

17. Subject weighs less than 50 lbs

18. Subject expects to have a medical procedure during the upcoming 8 weeks that estimates blood loss to exceed 400 cc for adults or for children would exceed 3 ml/kg

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Rochester General Hospital - Infectious Disease Unit	Rochester	New York	United States	14621-3001
2	University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases	Rochester	New York	United States	14642-0001

Sponsors and Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

None specified.

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Jan 25, 2021

More Information

Publications

None provided.

• Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
• ClinicalTrials.gov Identifier: NCT03328325
• Other Study ID Numbers: 16-0101; HHSN272201400005C; NCT03133936
• First Posted: Nov 1, 2017
• Last Update Posted: May 24, 2021
• Last Verified: Mar 3, 2021

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID): B Cell Response; Children; Evaluation; Healthy Adults; Influenza Vaccine
• Additional relevant MeSH terms: Influenza, Human; Vaccines

Study Results

Participant Flow

Recruitment Details	Healthy adults and children ages 9 and over

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Period Title: Overall Study
STARTED	152
COMPLETED	141
NOT COMPLETED	11

Baseline Characteristics

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Overall Participants	152
Age (Count of Participants)
<=18 years	23 15.1%
Between 18 and 65 years	109 71.7%
>=65 years	20 13.2%
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	43
Sex: Female, Male (Count of Participants)
Female	93 61.2%
Male	59 38.8%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	13 8.6%
Not Hispanic or Latino	139 91.4%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	6 3.9%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	4 2.6%
White	137 90.1%
More than one race	4 2.6%
Unknown or Not Reported	1 0.7%

Outcome Measures

1. Primary Outcome

Title	Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI)
Description	A/Hong Kong/4801/2014 (H3N2) day 28 Season 2017-2018
Time Frame	Through Day 28

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	18
Geometric Mean (Geometric Coefficient of Variation) [titer]	528 (1.38)

2. Primary Outcome

Title	Magnitude of the Serum Antibody Response by Microneutralization (MN)
Description	A/Hong Kong/4801/2014 (H3N2) Day 28 MN Season 2017-2018
Time Frame	Day 28

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	18
Geometric Mean (Geometric Coefficient of Variation) [titer]	806 (1.21)

3. Primary Outcome

Title	Serum Antibody Response by Hemagglutination-inhibition (HAI)
Description	A/Hong Kong/4801/2014 (H3N2) Day 90 Season 2017-2018
Time Frame	Day 90

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	17
Geometric Mean (Geometric Coefficient of Variation) [titer]	115 (3.08)

4. Primary Outcome

Title	Serum Antibody Response by Microneutralization (MN)
Description	A/Hong Kong/4801/2014 (H3N2) Day 90 MN Season 2017-2018
Time Frame	Day 90

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	17
Geometric Mean (Geometric Coefficient of Variation) [titer]	1389 (1.08)

5. Primary Outcome

Title	Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI)
Description	A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-2018
Time Frame	Day 28

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	18
Geometric Mean (Geometric Coefficient of Variation) [titer]	665 (1.73)

6. Primary Outcome

Title	Specificity of the Serum Antibody Response by Microneutralization (MN)
Description	A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-18
Time Frame	Day 28

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Measure Participants	18
Geometric Mean (Geometric Coefficient of Variation) [titer]	2281 (2.86)

7. Secondary Outcome

Title	Age at Time of First Influenza A Exposure
Description	Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not
Time Frame	Baseline

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

8. Secondary Outcome

Title	Baseline B Cell Reactivity
Description	Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not
Time Frame	Baseline

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

9. Secondary Outcome

Title	Vaccine History (Number and Percentage of Participants to Receive Vaccine)
Description	Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not
Time Frame	Baseline

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	6 months
Arm/Group Title	Arm 1
Arm/Group Description	0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240 Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013. Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
All Cause Mortality
	Arm 1
	Affected / at Risk (%)	# Events
Total	0/152 (0%)
Serious Adverse Events
	Arm 1
	Affected / at Risk (%)	# Events
Total	1/152 (0.7%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric Mass, S/P Wedge resection, GIST Sarcoma	1/152 (0.7%)	1
Other (Not Including Serious) Adverse Events
	Arm 1
	Affected / at Risk (%)	# Events
Total	24/152 (15.8%)
Infections and infestations
Upper Respiratory Tract Infection	24/152 (15.8%)	26

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.